The analysis was focused on perioperative factors, including operation time, blood loss, and conversion rates to open surgery ...

We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Substack by Steve Wagner | Invest. In this article, we ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

The FDA issued a second, expanded recall of duloxetine after higher than acceptable levels of a cancer-causing chemical were ...

This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...

An experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $12.00.Pick ...

PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

First-in-human results for three investigational inhibitors show anti-tumor activity without unmanageable effects on blood glucose.

The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...